January 23, 2019
As new treatments for multiple myeloma have extended patient survival—from an average of three years to more than 10 in some cases—physicians and researchers face a new challenge: how to predict a drug’s long-term effectiveness? How to tell, early on, whether one drug is likely to extend patients’ lives more than another? At Dana-Farber’s Jerome Lipper Multiple Myeloma...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand